March 2018 Issue Table Of Contents

From The Editor

• Do You Believe Print Publications Are Dead?

Feature Articles

• CYDAN: Mission In The Orphan Space
• What’s Next For Seattle Genetics?
• Intricate Supply Chain Complicates Gene Therapy Manufacturing

Capitol Perspectives

• Republicans Forsake Fiscal Restraint And Market-Based Healthcare

Companies To Watch

• AmpliPhi Biosciences
• Companies To Watch Roundup 2017

Industry Research

• The Evolution Of IRT

Inside The Industry

• Crowdfunding Fizzles As VC Soars
• Pharma Cybersecurity After NotPetya
• Study Proves Importance Of Patient Diversity In Clinical Trials
• What GDPR Means For U.S. Life Sciences Companies
• The Dynamics And Value Of Cross-Border Biotech
• GSK’s Bid To Accelerate Drug Discovery Using AI
• How Mesoblast Survived The Termination Of A Key Partnership, And Prospered
• Inspiring Trust In Industry Practices

Leadership Lessons

• Why Leaders Need To Be Paradox Navigators

Ask The Board

• What Do Biopharma Execs (Not Typically Involved In Manufacturing) Need To Understand About PUPSIT?
• What Are Some Challenges Of Patient-Driven Drug Development, And How Can They Be Overcome?
• When Is The Best Time To Implement A Secondary Manufacturing Sourcing Strategy?